NEXGEL, Inc. (NXGL)
NASDAQ: NXGL · IEX Real-Time Price · USD
2.210
-0.120 (-5.15%)
At close: Apr 26, 2024, 4:00 PM
2.100
-0.110 (-4.98%)
After-hours: Apr 26, 2024, 5:21 PM EDT
NEXGEL Revenue
In the year 2023, NEXGEL had annual revenue of $4.09M with 99.66% growth. Revenue in the quarter ending December 31, 2023 was $1.08M with 106.49% year-over-year growth.
Revenue (ttm)
$4.09M
Revenue Growth
+99.66%
P/S Ratio
3.37
Revenue / Employee
$215,211
Employees
19
Market Cap
13.76M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 4.09M | 2.04M | 99.66% |
Dec 31, 2022 | 2.05M | 497.00K | 32.04% |
Dec 31, 2021 | 1.55M | 877.00K | 130.12% |
Dec 31, 2020 | 674.00K | -43.00K | -6.00% |
Dec 31, 2019 | 717.00K | -1.50M | -67.60% |
Dec 31, 2018 | 2.21M | 221.00K | 11.09% |
Dec 31, 2017 | 1.99M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Trinity Biotech | 56.83M |
Star Equity Holdings | 45.79M |
Pieris Pharmaceuticals | 42.81M |
Psychemedics | 22.10M |
BIMI International Medical | 5.85M |
Mainz Biomed B.V. | 895.48K |
iBio, Inc. | 50.00K |
BioSig Technologies | 18.00K |
NXGL News
- 26 days ago - NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year - GlobeNewsWire
- 4 weeks ago - NEXGEL Reschedules Fourth Quarter and Full Year 2023 Financial Results Conference Call to Monday, April 1st at 8:30 a.m. ET Due to Holiday - GlobeNewsWire
- 5 weeks ago - NEXGEL to Report Fourth Quarter and Full Year 2023 Financial Results on March 28th - GlobeNewsWire
- 7 weeks ago - NEXGEL to Present at the iAccess Alpha Best Ideas Spring Virtual Conference on March 12th - GlobeNewsWire
- 3 months ago - NEXGEL Subsidiary, CG Converting and Packaging, Begins 12,000 Square Foot Expansion of Texas Facility to Support the Expected Growth in Product Demand in 2024 - GlobeNewsWire
- 4 months ago - NEXGEL Announces Partnership with STADA to Distribute and Commercialize Consumer Health OTC Products in North America - GlobeNewsWire
- 5 months ago - NEXGEL Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-Year - GlobeNewsWire
- 7 months ago - NEXGEL to Participate in the LD Micro Main Event XVI on October 3rd - GlobeNewsWire